CASE STUDY: Scientific expertise to solve technical roadblocks
A client was developing a new apheresis device. Monitoring complement activation after blood exposure, they found higher levels compared to historical experience. The client was concerned this would slow development of the device.
BioPhia was engaged to provide SME review of the in vitro complement activation data and provide insight into possible reasons for the apparent levels and suggest the next steps.
An initial meeting produced a document that explained the data in the context of extracorporeal blood contact and outlined a set of follow-up experiments to resolve any issues.
A white paper was generated that included background on complement activation, the original data and results from follow-up work. This was included as an addendum to an internal report on the device development project.